These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 29270718)

  • 41. Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice.
    Huang B; Wang W; Li R; Wang X; Jiang T; Qi X; Gao Y; Tan W; Ruan L
    Virol J; 2012 Dec; 9():322. PubMed ID: 23272943
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vaccination With Viral Vectors Expressing Chimeric Hemagglutinin, NP and M1 Antigens Protects Ferrets Against Influenza Virus Challenge.
    McMahon M; Asthagiri Arunkumar G; Liu WC; Stadlbauer D; Albrecht RA; Pavot V; Aramouni M; Lambe T; Gilbert SC; Krammer F
    Front Immunol; 2019; 10():2005. PubMed ID: 31497029
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of the antigenic relatedness and cross-protective immunity of the neuraminidase between human influenza A (H1N1) virus and highly pathogenic avian influenza A (H5N1) virus.
    Lu X; Liu F; Zeng H; Sheu T; Achenbach JE; Veguilla V; Gubareva LV; Garten R; Smith C; Yang H; Stevens J; Xu X; Katz JM; Tumpey TM
    Virology; 2014 Apr; 454-455():169-75. PubMed ID: 24725943
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge.
    Jimenez GS; Planchon R; Wei Q; Rusalov D; Geall A; Enas J; Lalor P; Leamy V; Vahle R; Luke CJ; Rolland A; Kaslow DC; Smith LR
    Hum Vaccin; 2007; 3(5):157-64. PubMed ID: 17637571
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Immunogenicity of recombinant proteins including ectodomain of M2 influenza virus A].
    Stepanova LA; Kovaleva AA; Potapchuk MV; Korotkov AV; Kupriianov VV; Blokhina EA; Kotliarov RIu; Tsybalova LM
    Vopr Virusol; 2013; 58(3):21-5. PubMed ID: 24006628
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains.
    Ryder AB; Nachbagauer R; Buonocore L; Palese P; Krammer F; Rose JK
    J Virol; 2015 Dec; 90(5):2544-50. PubMed ID: 26676789
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Heterosubtypic immunity to influenza mediated by liposome adjuvanted H5N1 recombinant protein vaccines.
    Thueng-in K; Maneewatch S; Srimanote P; Songserm T; Tapchaisri P; Sookrung N; Tongtawe P; Channarong S; Chaicumpa W
    Vaccine; 2010 Sep; 28(41):6765-77. PubMed ID: 20688037
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Single mucosal vaccination targeting nucleoprotein provides broad protection against two lineages of influenza B virus.
    Kim MH; Kang JO; Kim JY; Jung HE; Lee HK; Chang J
    Antiviral Res; 2019 Mar; 163():19-28. PubMed ID: 30639307
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein.
    Roy S; Kobinger GP; Lin J; Figueredo J; Calcedo R; Kobasa D; Wilson JM
    Vaccine; 2007 Sep; 25(39-40):6845-51. PubMed ID: 17728024
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice.
    Altenburg AF; van de Sandt CE; van Trierum SE; De Gruyter HLM; van Run PRWA; Fouchier RAM; Roose K; Saelens X; Volz A; Sutter G; de Vries RD; Rimmelzwaan GF
    J Virol; 2016 Nov; 90(22):10209-10219. PubMed ID: 27581985
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vaccine protection against lethal homologous and heterologous challenge using recombinant AAV vectors expressing codon-optimized genes from pandemic swine origin influenza virus (SOIV).
    Sipo I; Knauf M; Fechner H; Poller W; Planz O; Kurth R; Norley S
    Vaccine; 2011 Feb; 29(8):1690-9. PubMed ID: 21195079
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Protection against multiple influenza A virus subtypes by intranasal administration of recombinant nucleoprotein.
    Guo L; Zheng M; Ding Y; Li D; Yang Z; Wang H; Chen Q; Sui Z; Fang F; Chen Z
    Arch Virol; 2010 Nov; 155(11):1765-75. PubMed ID: 20652335
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran.
    Ebrahimi SM; Dabaghian M; Tebianian M; Jazi MH
    Virology; 2012 Aug; 430(1):63-72. PubMed ID: 22595444
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Vaccination with DNA encoding internal proteins of influenza virus does not require CD8(+) cytotoxic T lymphocytes: either CD4(+) or CD8(+) T cells can promote survival and recovery after challenge.
    Epstein SL; Stack A; Misplon JA; Lo CY; Mostowski H; Bennink J; Subbarao K
    Int Immunol; 2000 Jan; 12(1):91-101. PubMed ID: 10607754
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Programming of Influenza Vaccine Broadness and Persistence by Mucoadhesive Polymer-Based Adjuvant Systems.
    Noh HJ; Chowdhury MY; Cho S; Kim JH; Park HS; Kim CJ; Poo H; Sung MH; Lee JS; Lim YT
    J Immunol; 2015 Sep; 195(5):2472-82. PubMed ID: 26216889
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Virus-like particle vaccine comprised of the HA, NA, and M1 proteins of an avian isolated H5N1 influenza virus induces protective immunity against homologous and heterologous strains in mice.
    Tao P; Luo M; Zhu D; Qu S; Yang Z; Gao M; Guo D; Pan Z
    Viral Immunol; 2009 Jul; 22(4):273-81. PubMed ID: 19594398
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of seasonal pandemic influenza hemagglutinin DNA vaccines delivered by electroporation against a seasonal H1N1 virus challenge in mice.
    Tan L; Lu H; Zhang D; Wang K; Tian M; Liu C; Liu Y; Hu B; Jin N
    Sci China Life Sci; 2011 Apr; 54(4):293-9. PubMed ID: 21416231
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A live attenuated H1N1 M1 mutant provides broad cross-protection against influenza A viruses, including highly pathogenic A/Vietnam/1203/2004, in mice.
    Xie H; Liu TM; Lu X; Wu Z; Belser JA; Katz JM; Tumpey TM; Ye Z
    J Infect Dis; 2009 Dec; 200(12):1874-83. PubMed ID: 19909080
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies.
    Lo CY; Wu Z; Misplon JA; Price GE; Pappas C; Kong WP; Tumpey TM; Epstein SL
    Vaccine; 2008 Apr; 26(17):2062-72. PubMed ID: 18378366
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reduction of influenza virus transmission from mice immunized against conserved viral antigens is influenced by route of immunization and choice of vaccine antigen.
    Price GE; Lo CY; Misplon JA; Epstein SL
    Vaccine; 2018 Aug; 36(32 Pt B):4910-4918. PubMed ID: 30037481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.